Gyre Therapeutics Inc Stock price
Compare with Peer Group
AI Insights on Gyre Therapeutics Inc
Insights
Is Gyre Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,102 stocks worldwide.
Key metrics
Gyre Therapeutics Inc Stock Analysis
Analyst Opinions
9 Analysts have issued a Gyre Therapeutics Inc forecast:
Analyst Opinions
9 Analysts have issued a Gyre Therapeutics Inc forecast:
Don't miss a Thing! We will send you all news about Gyre Therapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Gyre Therapeutics Inc Stock News
Company Profile
Gyre Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 618 full-time employees. The company went IPO on 2006-04-12. The company is also advancing a diverse pipeline in the PRC through its controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, and F528. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. The company is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. The company is also focused on commercializing the avatrombopag product and discovery and development of targeted protein degrader and degrader antibody conjugate therapies.
| Head office | United States |
| CEO | Mr. Zhang |
| Employees | 625 |
| Website | www.gyretx.com |


